Tannate compositions consisting essentially of carbetapentane tannate and pyrilamine tannate which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis, unproductive cough and upper respiratory tract conditions are disclosed.

FIELD OF INVENTION
 The invention relates to novel antihistaminic and antitussive tannate
 compositions. The compositions contain as essential ingredients
 carbetapentane tannate and pyrilamine tannate.
 BACKGROUND OF INVENTION
 A considerable number of tannic acids occur in nature. Chemically, these
 acids are described as polymers of different hydroxybenzoic acids.
 Generally, when the term tannic acid is employed, as in the present case,
 the acid referred to is gallotannic acid, the internal ester of gallic
 acid also frequently referred to as tannin.
 Tannic Acid consists of an amorphous powder glistening scales or spongy
 masses varying in color from yellowish-white to light brown. Tannic acid
 is very soluble in water, glycerine or alcohol.
 Tannic acids are usually obtained from glycosides which consist of several
 molecules of a tannic acid in combination with glucose.
 Commercially available, tannic acid, also known as Tannin, has a complex
 non-uniform chemistry usually contains from about 5% to about 10% by
 weight water, has a molecular weight of about 1700 and is typically
 produced from Turkish or Chinese nutgall.
 Carbetapentane, 2-(2-diethylaminoethoxy)ethyl-1 phenylcyclopentane
 carboxlate is an antitussive compound that is described in U.S. Pat. No.
 2,842,585 and is structurally related to caramiphen. Carbetapentane
 citrate has a melting point of 93.degree. C. and occurs as a white powder
 freely soluble in water and slightly soluble in alcohol.
 Carbetapentane has an atropine-like action that depresses the cough reflex
 by selective central nervous system depression.
 Pyrilamine is one of the oldest and most enduring antihistaminic drugs,
 known chemically as
 N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine
 , its preparation is disclosed in U.S. Pat. No. 2,502,151 and is an oily
 liquid. Pyrilamine hydrochloride salt is very soluble in water and has a
 melting point of 143-143.50.degree. C. whereas the maleate salt is
 slightly soluble in water, benzene and ether and has a melting point of
 100-101.degree. C.
 Antihistamine compounds in the form of their free bases as well as their
 salts, e.g. hydrochloride, citrate, maleate, tannate, etc., are well
 known. Antihistamines in the form of their tannate salts are very
 desirable because such salts are generally stable and may be combined in
 such form without any untoward side effects.
 Antihistaminics and antitussives in the form of their tannate salts are
 typically prepared by reacting the free base, e.g. pyrilamine,
 carbetapentane, etc. with tannic acid in the presence of a volatile
 solvent, usually isopropanol. Typically, in the conventional isopropanol
 route, the decongestant or antihistaminic free base and the tannic acid
 will be present in the isopropanol at a concentration of about 20% based
 on the weight of the reaction mixture. The reaction mixture is stirred for
 about one hour while maintaining the mixture at 60-70.degree. C. The
 reaction mixture is cooled to room temperature and then filtered, washed
 with isopropanol and then vacuum dried. Alternative routes to the tannate
 salts are described in U.S. Pat. Nos. 5,599,846 and 5,663,415.
 THE INVENTION
 It has now been found that the novel combination of carbetapentane tannate
 and pyrilamine tannate produces a composition having antitussive and
 antihistaminic properties superior to the use of either one of the tannate
 compounds alone.
 The compositions of the present invention may be prepared for oral
 administration in the form of powders, capsules, elixirs, syrups and the
 preferred forms of tablets formulated so that ideally each tablet contains
 about 50 mg to about 75 mg, preferably about 60 mg of carbetapentane
 tannate and about 50 mg to about 75 mg, preferably about 60 mg pyrilamine
 tannate or suspensions formulated so that ideally each 5 mL (approximately
 1 teaspoon) of suspension would contain approximately 20 to 30 mg
 carbetapentane tannate and an equal amount of pyrilamine tannate.
 Tablets containing the unique tannate combination of the present invention
 are prepared in a conventional manner by the addition of suitable
 pharmaceutical carriers including fillers, diluents, colorants, lubricants
 and the like as well as conventional and well known binding and
 disintegrating agents. A typical tablet composition of the present
 invention containing starch, dibasic calcium phosphate, coloring,
 magnesium stearate, methylcellulose, polygalacturonic acid, povidone and
 talc as described in Example 1 which follows is prepared by well known
 conventional tabletting techniques such as those disclosed in U.S. Pat.
 Nos. 3,018,221; 2,798,024 and 2,757,124.

Carbetapentane Tannate 20-30 mg
 Pyrilamine Tannate 20-30 mg
 The suspension formulations additionally contain benzoic acid, coloring,
 natural and artificial flavors, glycerin, kaolin, magnesium aluminum
 silicate, methyl paraben, pectin, purified water, saccharin, sodium
 hydroxide, tannic acid and sucrose or sorbitol.
 Example 2, which follows, is illustrative of a typical suspension
 formulation of the present invention prepared by conventional well known
 compounding techniques.
 EXAMPLE 2

Ingredient Milligrams per 5 mL
 CarbetapentaneTannate 30.0
 Pyntamine Tannate 30.0.sup.1
 Pectin, USP (Medium Viscosity) 50.0
 Kaotin, USP (Colloidal Powder) 1000
 Magnesium Aluminum Siticate, NF 35.0
 Benzoic Acid, USP 10.0
 Methytparaben, NF 5.0
 Sucrose, NF 1000
 Saccharin Sodium, USP 0.75
 Glycerin, USP 225
 Flavor Black Currant Imitation 0.91
 Flavor Strawberry with Other Natural Flavors 2.28
 Purple Shade "R" Dye 0.45
 FD&C Red #3 Dye 0.8
 FD&C Yellow #5 0.3
 Sodium Hydroxide Sotution-50% 3.17.sup.2
 Purified Water, USP (Deionized) adjust to 5 ml
 .sup.1 5% excess added during manufacturing
 .sup.2 The quantity of Sodium Hydroxide Solution may be varied depending on
 the pH of the Kaolin used in the batch. Tannic acid may also be used in
 lieu of sodium hydroxide solution for pH adjustment.
 .sup.3 Sodium Citrate, USP, Dihydrate and Citric Acid, usp, Anhydrous may
 also be included in the formula for pH adjustment.
 For the purpose of this disclosure, a warm-blooded animal is a member of
 the animal kingdom possessed of a homeostatic mechanism and includes
 mammals and birds.
 The dosage administered will be dependent on the age, health and weight of
 the recipient, kinds of concurrent treatment, if any, frequency of
 treatment and effect desired.
 It should be understood that the above examples are illustrative of the
 best mode only of the invention herein disclosed. Given the present
 disclosure, it is anticipated that numerous variations will occur to those
 skilled in the art. A latitude of modification, substitution and change is
 intended and in some instances, some features of the invention will be
 employed without a corresponding use of other features. Accordingly, it is
 intended that the spirit and scope of the invention disclosed herein
 should be limited only by the following claims.